Page last updated: 2024-10-26

dipyridamole and Esophageal Neoplasms

dipyridamole has been researched along with Esophageal Neoplasms in 1 studies

Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.

Esophageal Neoplasms: Tumors or cancer of the ESOPHAGUS.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fisher, RS1
Cohen, S1

Other Studies

1 other study available for dipyridamole and Esophageal Neoplasms

ArticleYear
Disorders of the lower esophageal sphincter.
    Annual review of medicine, 1975, Volume: 26

    Topics: Acetylcholine; Chagas Disease; Dipyridamole; Esophageal Achalasia; Esophageal and Gastric Varices; E

1975